

Age Restriction to be Updated in the TMPPM for Hympavzi (Marstacimab-hncq)

Last updated on 8/19/2026

On October 1, 2026, the Texas Medicaid & Healthcare Partnership (TMHP) will update the *Texas Medicaid Provider Procedures Manual (TMPPM)*, *Outpatient Drug Services Handbook*, section 6.61.6, “Hympavzi (Marstacimab-hncq),” to align the age restriction with the restriction on the U.S. Food and Drug Administration (FDA) label.

The age for *Hympavzi* (marstacimab-hncq) (procedure code J7172) will be updated from 12 years of age or older to 6 years of age or older.

For more information, call the TMHP Contact Center at 800-925-9126.

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.

[Return to top](#)



Helpful Links

[About TMHP](#)
[Privacy/HIPAA](#)
[Terms and Conditions](#)

Support

[Contact Us](#)
[Reporting Fraud](#)
[Help](#)